- Trials with a EudraCT protocol (7,054)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7,054 result(s) found for: Prior Placebo.
Displaying page 286 of 353.
EudraCT Number: 2019-002713-19 | Sponsor Protocol Number: VIB4920.P2.S2 | Start Date*: 2020-01-15 | |||||||||||
Sponsor Name:Viela Bio, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS) | |||||||||||||
Medical condition: Sjögren's syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000494-36 | Sponsor Protocol Number: AC-083-103 | Start Date*: 2017-07-26 |
Sponsor Name:Idorsia Pharmaceuticals Ltd | ||
Full Title: A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy | ||
Medical condition: Photosensitive epilepsy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014543-36 | Sponsor Protocol Number: AC4113073 | Start Date*: 2009-11-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014586-75 | Sponsor Protocol Number: D0520C00020 | Start Date*: 2009-12-21 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60 mg AZD9668 Administered Orally Twice Daily to Subje... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022280-35 | Sponsor Protocol Number: SSD113434 | Start Date*: 2010-11-22 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis. | |||||||||||||
Medical condition: subjects with moderate or severe atopic dermatitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001066-17 | Sponsor Protocol Number: CNTO1959PSO2001 | Start Date*: 2012-04-10 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X... | |||||||||||||
Medical condition: Moderate to Severe Plaque-type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005549-39 | Sponsor Protocol Number: EHT 0202/002 | Start Date*: 2007-12-19 | |||||||||||
Sponsor Name:EXONHIT | |||||||||||||
Full Title: A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg ... | |||||||||||||
Medical condition: Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015817-31 | Sponsor Protocol Number: OC3-DB-02 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:OxThera IP AB | |||||||||||||
Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria | |||||||||||||
Medical condition: primary hyperoxaluria | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021430-64 | Sponsor Protocol Number: RR10/9389 | Start Date*: 2010-12-03 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome. | |||||||||||||
Medical condition: Primary Sjögren’s syndrome (PSS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012213-22 | Sponsor Protocol Number: PHX1149-PROT306 | Start Date*: 2009-11-11 | |||||||||||
Sponsor Name:Phenomix Corporation | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Rena... | |||||||||||||
Medical condition: Type II Diabetes Mellitus in subjects with Moderate and Severe Renal Impairment including subjects on Hemodialysis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006690-25 | Sponsor Protocol Number: OTCS-CE-301 | Start Date*: 2007-02-09 | |||||||||||
Sponsor Name:Novartis Consumer Health SA | |||||||||||||
Full Title: A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-being of Otrivin F2 ... | |||||||||||||
Medical condition: nasal congestion associated with the common cold | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005228-24 | Sponsor Protocol Number: 402-C-327 | Start Date*: 2016-06-10 | |||||||||||
Sponsor Name:Pacira Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block with EXPAREL for Postsurgical Analgesia in Subjects ... | |||||||||||||
Medical condition: Total Shoulder Arthroplasty or Rotator Cuff Repair | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000343-33 | Sponsor Protocol Number: 248.641 | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investig... | |||||||||||||
Medical condition: Tourette's Syndrome (TS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010221-39 | Sponsor Protocol Number: MB102035 | Start Date*: 2009-12-18 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control ... | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000429-58 | Sponsor Protocol Number: M/100977/25 | Start Date*: 2011-08-10 | |||||||||||
Sponsor Name:Almirall S.A. | |||||||||||||
Full Title: A PHASE IIA, RANDOMISED, SINGLE DOSE, DOUBLE-BLIND, DOUBLE-DUMMY, 6 WAY COMPLETE CROSS-OVER, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF 4 STRENGTHS OF LAS1... | |||||||||||||
Medical condition: Stable moderate to severe chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002905-31 | Sponsor Protocol Number: RO-2455-405-RD | Start Date*: 2011-12-01 | ||||||||||||||||
Sponsor Name:Nycomed GmbH | ||||||||||||||||||
Full Title: Effect of roflumilast 500 μg tablets once daily at acute COPD exacerbations treated with standard therapy of oral steroids and antibiotics. A randomised, double-blind, placebo-controlled, parallel-... | ||||||||||||||||||
Medical condition: Acute exacerbations of chronic obstructive pulmonary disease (COPD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006236-23 | Sponsor Protocol Number: 311-09 | Start Date*: 2012-07-02 | |||||||||||
Sponsor Name:Accord Healthcare Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-centre, Therapeutic Equivalence Study of Two Tacrolimus 0.1% Topical Ointment Formulations in Adult Patients wi... | |||||||||||||
Medical condition: moderate to severe atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013408-30 | Sponsor Protocol Number: 2009-013408-30 | Start Date*: 2010-08-23 | |||||||||||||||||||||
Sponsor Name:University College London | |||||||||||||||||||||||
Full Title: Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers | |||||||||||||||||||||||
Medical condition: biliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003812-19 | Sponsor Protocol Number: ZPL389/102 | Start Date*: 2015-12-07 | |||||||||||
Sponsor Name:Ziarco Pharma Ltd | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT ... | |||||||||||||
Medical condition: PLAQUE PSORIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000053-23 | Sponsor Protocol Number: SP0977 | Start Date*: 2011-08-17 | |||||||||||
Sponsor Name:UCB Biosciences GmbH | |||||||||||||
Full Title: Multicenter, double-blind, placebo-controlled, two-arm, randomized, parallel, treatment intervention, sleep lab phase 4 study to assess the effect of rotigotine on nocturnal blood pressure in patie... | |||||||||||||
Medical condition: Restless Legs Syndrome (RLS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
